Crk-associated substrate lymphocyte type (Cas-L) is a 105 kDa docking protein with diverse functional properties, including regulation of cell division, proliferation, migration and adhesion. Cas-L is also involved in b1 integrin-or antigen receptor-mediated signaling in B and T cells. In the present study, we demonstrate that Cas-L potentiates transforming growth factor-b (TGF-b) signaling pathway by interacting with Smad6 and Smad7. Immunoprecipitation experiments reveal that single domain deletion of full-length Cas-L completely abolishes its docking function with Smad6 and Smad7, suggesting that the natural structure of Cas-L is necessary for its association with Smad6 and Smad7. On the other hand, both N-terminal and C-terminal deletion mutants of Smad6 and Smad7 still retain their docking ability to Cas-L, suggesting that Smad6 and Smad7 possess several binding motifs to Cas-L. Moreover, Cas-L interaction with Mad-homology (MH)2 domain, but not with MH1 domain of Smad6 or Smad7, ameliorates TGF-b-induced signaling pathway. Finally, depletion of Cas-L by smallinterfering RNA oligo attenuates TGF-b-induced growth inhibition of Huh-7 cells, with a concomitant reduction in phosphorylation of Smad2 and Smad3. These results strongly suggest that Cas-L is a potential regulator of TGF-b signaling pathway. Oncogene (2007) 26, 893-904.
Introduction
b1 integrins exhibit a variety of biological functions through specific interaction with their ligands (Hynes, 1992; Juliano and Haskill, 1993) . We previously demonstrated that the 105 kDa protein (pp105) termed Cas-L (Cas lymphocyte type) (Minegishi et al., 1996) or human enhancer of filamentation 1 (HEF1) (Law et al., 1996) is a focal adhesion kinase (FAK)-associated docking protein that is heavily tyrosine phosphorylated by FAK and Src family kinases upon engagement with b1 integrin and the T-cell antigen receptor complex in T cells (Minegishi et al., 1996; Tachibana et al., 1997; Ohashi et al., 1998) . Transfection of Cas-L into Jurkat cells markedly enhanced cell motility and interleukin-2 production following b1 integrin engagement. These results clearly indicate that Cas-L plays a key role in b1 integrin-mediated signal transduction and cell migration.
The transforming growth factor-b (TGF-b) superfamily of cytokines has diverse functional roles during embryonic development and tissue homeostasis (Derynck and Zhang, 2003) . Disruption of TGF-b signaling is responsible for a number of developmental disorders (Datta and Moses, 2000) , fibrotic diseases (Yagil et al., 2005) and human cancers (Kato et al., 2002) . Although TGF-b acts as a tumor suppressor (Kato et al., 2002) , it also plays opposite roles in tumor progression. As carcinogenesis proceeds and tumor cells acquire resistance to TGF-b-induced growth arrest, TGF-b accelerates cancer cell progression. Therefore, it is quite important to control the sensitivity to TGF-b for regulation of growth of cancer cells. The TGF-b superfamily transmits signals via cell surface complexes of type I and type II receptor serine/threonine kinase and intracellular Smad transcription factors, which are classified into three functional groups (Derynck and Zhang, 2003) . Receptor-regulated Smads and R-Smads (Smad1, 2, 3, 5 and 8) are phosphorylated by type I receptor and oligomerize with the common mediator, Co-Smad (Smad4) (Gro¨nroos et al., 2002; Sugano et al., 2003) . These heteromeric complexes are translocated into the nucleus to regulate gene transcription by either association with DNA-binding proteins or direct binding to promoter sequences in target genes (Sugano et al., 2003) . On the other hand, inhibitory-Smads, I-Smads (Smads6 and 7) are negative signal regulators that block R-Smad phosphorylation by the type I receptor, concomitantly inducing type I receptor dephosphorylation and proteasomal degradation (Heldin et al., 1997; Nakao et al., 1997; Chacko et al., 2004) .
We recently demonstrated that Cas-L is upregulated in human T-lymphotropic virus type I (HTLV-I) Tax transgenic mice (Miyake-Nishijima et al., 2003) , and that Cas-L regulates Tax-nuclear factor-kB pathway by direct interaction with Tax . Cas-L was previously reported to be involved in TGF-b signaling pathway. For example, under certain circumstances, TGF-b induces gene transcription and protein expression of Cas-L with no effect on the stability of either Cas-L protein or mRNA (Fashena et al., 2002) , whereas in other experimental conditions, TGF-b promotes proteosomal degradation of Cas-L (Zhang et al., 2000) . However, the biological significances of Cas-L in TGF-b signaling remain to be clarified. Our search for putative Cas-L associated proteins to further investigate the biological role of Cas-L led to the identification of Smad6 and Smad7, the negative signal regulators of TGF-b signaling pathways. In this study, we determined the functional significance of Cas-L interaction with I-Smads, Smad6 and Smad7. We found that Cas-L facilitates TGF-b signaling, and that the mechanism responsible for this effect appears to be the abrogation of recruitment of I-Smads to TGF-b type I receptor induced by the Cas-L-I-Smads interaction, subsequently, resulting in the acceleration of activated R-Smads by TGF-b. On the basis of our findings, we propose that the Cas-L can confer sensitivity to TGF-b, with implications for cell development, immune response, inflammatory disease and tumor biology.
Results

Cas-L interacts with Smad6 and Smad7
To understand the biological significance of Cas-L, we performed yeast two-hybrid cDNA cloning in search for Cas-L binding proteins as described previously . We screened over 1 Â 10 6 independent clones from the cDNA library of the lymphoblastic cell line SLB-I. Among 180 clones selected by histidine auxotrophy and b-galactosidase (b-gal) expression, we identified a clone containing Smad7 cDNA (aa 203-353) in frame with GAL4 activator domain.
We next examined the association of exogenous Cas-L protein with Smad6 and Smad7. Unlike the results from the yeast two-hybrid assay using SLB-I cDNA library, co-transfection study with 293 T cells using flag-tagged Smad6 or Smad7 with c-myc-tagged Cas-L revealed that Cas-L specifically immunoprecipitated with both Smad6 and Smad7 before TGF-b treatment ( Figure 1a ). This discrepancy arose from the cell-type specific differentially expressed transcripts (Supplementary Figure 1) . Moreover, immunoprecipitation study of endogenous proteins revealed that the amount of Cas-L binding to Smad6 was increased with increasing doses of TGF-b (Figure 1b, upper panels) . Similarly, endogenous Smad7-Cas-L binding was accelerated by TGF-b treatment (Figure 1b, lower panels) .
To further investigate the intracellular events associated with the interaction of these proteins after TGF-b treatment, we next examined colocalization of Cas-L and I-Smads using confocal microscopy. Co-transfection study of flag-tagged Smad7 with c-myc-tagged Cas-L showed that Smad7 and Cas-L were dynamically colocalized in the cytoplasm, but not in the nucleus, following TGF-b treatment, with Smad7 gradually localizing in the cytoplasm (Figure 1c ). Colocalization of Smad6 and Cas-L was also upregulated by TGF-b treatment (data not shown). These results thus suggested that Cas-L associates with both Smad6 and Smad7, with the association between Cas-L and both Smad6 and Smad7 being accelerated by TGF-b treatment.
Cas-L counteracts I-Smads-induced inhibition of transcriptional activity by TGF-b As Cas-L interacted with Smad6 and Smad7, we further examined the functional consequences of Cas-L on TGF-b-induced transcriptional activity using reporter assay. As seen in Figure 2a , lane 7, Cas-L merely upregulated the basal (endogenous) transcriptional activity. Importantly, constitutively active activinreceptor-like kinase-5 (ALK5) (a mimicry of TGF-b) exaggerated the Cas-L-induced upregulation of transcriptional activity in a dose-dependent manner, suggesting that Cas-L induced TGF-b-mediated transcriptional activation (Figure 2a , lanes 8 and 9). Smad7 is known to be more potent than Smad6 in inhibiting TGF-b, whereas Smad6 is more potent than Smad7 to another TGF-b superfamily bone morphogenetic protein (Derynck et al., 2001) . As seen in Figure 2a , lanes 3-6, Smad7 inhibited transcriptional activity more strongly than Smad6, with constitutively active ALK5 having a markedly enhancing effect. Importantly, Cas-L counteracted the transcriptional inhibition by Smad6 (Figure 2a 
Full length of Cas-L is necessary for the interaction with Smad6 or Smad7
Cas-L is a multifunctional docking protein with several domain structures specific for Cas family members. To define the particular domain structures of Cas-L necessary for the interaction with Smad6 or Smad7, deletion mutants of each domain or conserved motif of Cas-L protein were constructed. C-myc-tagged fulllength Cas-L or mutant Cas-L cDNA subcloned into pEB6 vector was co-transfected with flag-tagged fulllength Smad6 or Smad7 in 293 T cells. Full-length Cas-L (Cas-L wild type (wt)) co-precipitated with Smad6
( Figure 4a ). Among the various mutants, only Cas-L F co-precipitated with Smad6 and Smad7, although its interaction with these proteins was weaker than Cas-L wt (Figure 4a and b) . These results were verified by three independent tests, suggesting that the natural structure of Cas-L itself is necessary for its interaction with Smad6 or Smad7. Expanding on these results, each Cas-L mutant was tested for its effect on sensitivity to TGFb using an in vitro proliferation model. Cas-L wt and Cas-L F enhanced sensitivity of Huh-7 cells to TGF-b, with other mutants and control vector having no effect (Figure 4c ). Together with the immunoprecipitation Cas-L in TGF-b signaling S Inamoto et al results, these data clearly indicated that Cas-L F was weaker than Cas-L wt in its ability to enhance cellular sensitivity to TGF-b (Figure 4c ), hence demonstrating the importance of the natural structure of Cas-L in its interaction with Smad6 or Smad7 and subsequent effect on TGF-b sensitivity.
Both C-terminal and N-terminal of Smad6 and Smad7 can interact with Cas-L Smad6 and Smad7 have conserved domain structure, namely N-terminal Mad-homology (MH)1 domain and C-terminal MH2 domain (Figure 5a ). We next employed flag-tagged Smad6 lacking MH1 domain (Smad6C), flag-tagged Smad6 lacking MH2 domain (Smad6N) and flag-tagged full-length Smad6 (Smad6F) in order to determine the binding domain of Smad6 to Cas-L. Smad7 mutants were also used in the same manner.
C-myc-tagged Cas-L was co-precipitated with Smad6F, Smad6C and Smad6N. Likewise, Smad7F, Smad7C and Smad7N were all co-precipitated with Cas-L (Figure 5b ). To further explore the functional significance of the above results, Huh-7 cells co-transfected with mutants of I-Smads and pEB6 vector or Cas-L were subjected to in vitro proliferation assay with TGF-b. pEB6 vector plus Smad6F or Smad6C had weaker growth inhibitory effect than pEB6 vector plus pcDEF vector (Figure 5c,  lanes 1, 3 and 5) . Importantly, Cas-L plus pcDEF vector exhibited additive growth inhibitory effect (Figure 5c , lane 2). Moreover, Cas-L plus Smad6F or Smad6C counteracted the inhibitory effect of Smad6F or Smad6C on TGF-b-induced growth arrest (Figure 5c , lanes 4 and 6). It should be noted that the effect of Cas-L plus Smad6N did not differ from that of pEB6 plus Smad6N (Figure 5c, lanes 7 and 8) , indicating that 
Discussion
In this report, we demonstrated that Cas-L interacts with two different I-Smads, Smad6 and Smad7, to counteract the antagonistic effect of I-Smads on TGF-b signaling. Furthermore, the attenuation of I-Smad function by Cas-L depends on interference with the recruitment of I-Smads to the TGF-b type I receptor.
Although TGF-b is reported to be a tumor suppressor during carcinogenesis, it also plays an opposite role in some tumors, depending on their origins and stages (Kato et al., 2002) . This finding suggests the existence of a cellular framework that allows for disruption of subcellular signaling molecules associated with TGF-b involvement in carcinogenesis. For example, certain gastrointestinal tumors have mutations in genes encoding components of the TGF-b signaling pathway, associated with aberrant growth of cancer cells. Defining the molecular basis for TGF-b unresponsiveness in tumors is therefore an important goal in further understanding cancer biology.
Our present work suggests that Cas-L activates TGF-b signaling pathway by interacting with the I-Smads, Smad6 and Smad7. Furthermore, Cas-L upregulates TGF-b-mediated transcriptional activity in gene reporter assays. Notably, genetically introduced Cas-L overcomes the Smad6 and Smad7-induced suppression of TGF-b-mediated SBE-luciferase reporter gene activity in 293 cells, suggesting that the underlying mechanism of Cas-L-induced sensitivity to TGF-b signaling is a loss of I-Smads function. Together with these results, overexpression of Cas-L protein results in an additive sensitivity to TGF-b. In support of this notion, depletion of Cas-L by siRNA oligo overcomes TGF-binduced growth inhibition in Huh-7 cells, associated with decreased levels of TGF-b-induced phosphorylation of Smad2 and Smad3. Taken together, the above results strongly suggest that Cas-L is a positive regulator of TGF-b signaling.
Importantly, Cas-L interaction with Smad6 and Smad7 depends largely on the full integrity of its protein structure, as mutants lacking SH3 domain, substrate domain, serine-rich lesion and C-terminal all lose their binding affinity for Smad6 and Smad7, whereas only mutant whose Y629 and Y631 residues are mutated into F (FDFVHL) weakly interacts with Smad6 and Smad7. A unique aspect of our data is that the observed Cas-L/ I-Smad interaction is not based on specific Cas-L domain, whereas other substrates for Cas-L, including FAK, Crk and Src, interact with its SH3 domain, substrate domain and YDYVHL motif, respectively (Tachibana et al., 1997; Ohashi et al., 1998) . Additional supporting evidence is that only wt Cas-L, and not the mutants lacking the aforementioned domains, affects the sensitivity of Huh-7 cells to TGF-b. Of note is that the addition of the same mutant whose Y629 and Y631 residues are mutated into F (FDFVHL) retains cellular sensitivity to TGF-b.
Although Cas-L mutants except for Cas-L F do not bind to Smad6 and Smad7, all deletion mutants of Smad6 or Smad7 still retain their binding affinity to fulllength Cas-L, suggesting that both MH1 and MH2 domains contain the binding motif for Cas-L. The fact that overexpressed Smad6 and Smad7 colocalize with Cas-L predominantly in the cytoplasm suggests that Cas-L/I-Smads interaction induces enhanced sensitivity to TGF-b outside the nucleus. Our work also indicates that Cas-L/I-Smads interaction influences the recruitment of I-Smads to TGF-b type I receptor. In the A member of the Cas family proteins, which include p130Cas, Efs/Sin and Cas-L/HEF1, Cas-L has a described physiological role at focal adhesion sites (Ohashi et al., 1998) . Accumulating evidence strongly suggests that Cas-L is a multifunctional docking protein, with a role in cell motility (van Seventer et al., 2001; Seo et al., 2005) , cytokine production , cell shape change , cell cycle (Astier et al., 1997) and cell division (Pugacheva and Golemis, 2005) , besides cell adhesion. Cas-L overexpression also induces apoptosis in HeLa cells, implying a potential role as a tumor suppressor . As tumor cells can develop resistance to TGF-bmediated growth inhibition, it is conceivable that Cas-L plays a role in this process. We have found that several cancer cell lines exhibit profoundly impaired endogenous Cas-L (data not shown). In addition, previous work has reported that Huh-7 cells possessing detectable level of Cas-L protein are highly sensitive to TGF-b, whereas Jurkat cells possessing sparse level of Cas-L are not responsive to TGF-b treatment (Hayashi et al., 1997; Lee et al., 2002) . It was previously shown that Cas-L binds to R-Smad, Smad3, with being proteasomally degraded by Smad3, and that overexpression of Cas-L in A549 cells results in inhibition of transcriptional activity in TGF-b signaling (Liu et al., 2000) . This discrepancy may be explained by that the cell typespecific abundance of subcellular downstream molecules in TGF-b signaling, including R-Smad/I-Smad ratio (Ito et al., 2001) , SARA (Xu et al., 2000a) or Ski (Xu et al., 2000b) , which differently regulate TGF-b signaling in a complex manner. Moreover, previous work identified a splice variant of Smad6 that is differentially regulated in diseased tissues and appears to be a TGF-b pathway activator, in contrast to wt Smad6 (Krishnan et al., 2001) . Further studies are needed to examine the involvement of these molecules with Cas-L/I-Smads interaction in TGF-b signaling. Our data, together with previous work on TGF-bmediated proteasomal degradation, suggest that the interaction of Cas-L with not only Smad3 but also Smad6 and Smad7, may be an essential part of an endogenous response aimed to limit the consequences of TGF-b refractoriness frequently observed in aggressive cancer cells.
In conclusion, our study indicates that Cas-L is a binding partner for Smad6 and Smad7, and that Cas-L potentiates TGF-b signaling mainly through its interaction with I-Smads. In view of the pivotal roles of TGF-b signaling in the pathophysiology of various diseases, studying Cas-L may therefore shed light on understanding the etiology of such conditions as cancer and connective tissue diseases.
Materials and methods
Reagents and antibodies
Rabbit polyclonal antibody against Cas-L was developed in our laboratory as described previously . Anti-c-myc tag monoclonal antibody (mAb) (9E10) was produced from the hybridoma obtained from the American Type Culture Collection (Manassas, VA, USA). Rabbit monoclonal antibodies to phosphorylated forms of Smad2 and Smad3, and mouse monoclonal antibodies to b-actin are all from Cell Signaling Technology Inc. (Beverly, MA, USA). Mouse monoclonal anti-Smad2/3 is from BD PharMingen (Lexington, KY, USA). Anti-Smad6 and Smad7 are from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Depletion of endogenous Cas-L
To deplete endogenous Cas-L, siRNA-oligo targeting Cas-L cDNA (accession no. NM_006403) was made according to the design site of TAKARA BIO (http://www.takara-bio.co.jp/ RNAi.htm); sense: 5 0 -GGAUGGAUGACUACGAUUA TT-3 0 , antisense: 3 0 -TT CCUACCUACUGAUGCUAAU-5 0 , with its scrambled control oligo which contains the same GC quantity; sense: 5 0 -UAAUUAGGGUCGGGUAAAC TT-3 0 , antisense: 3 0 -TT AUUAAUCCCAGCCCAUUUG-5 0 . Cas-L siRNA oligo (siCas-L) was transfected using TransIT-TKO transfection reagent (Mirus Bio Corporation, Madison, WI, USA) according to the manufacturer's protocol.
Cells, plasmids and transfection procedures
Huh-7 cells (human hepatocellular carcinoma) were obtained from Cell Resource Center for Biomedical Research, Tohoku University, Sendai, Japan. 293 T cells were obtained from the American Type Culture Collection (Rockville, MD, USA). The plasmid vectors used in exploring signaling pathway were as follows: c-myc tagged full-length Cas-L in a pEB6 vector (Cas-L wt) (pEB6 vector is a kind gift from Y Miwa, University of Tsukuba, Tsukuba, Japan) (Tanaka et al., 1999) , pEB6-c-myc-Cas-L DSH3 domain lacking aa 1-60 (Cas-L DSH3), pEB6-c-myc-CasL DSD domain lacking aa 63-401 (Cas-L DSD), pEB6-c-myc-Cas-L DC lacking aa 406-834 (Cas-L DC) and pEB6-c-myc-Cas-L F, in which Y629 and Y631 were mutated into F (Cas-L F), respectively. pcDEF3-Flag (N)-Smad7 (aa 1-427), pcDEF3-Flag-Smad7C (aa 247-427), pcDEF3-Flag-Smad7N (aa 1-259), pcDEF3-Flag-Smad6 (aa 1-496), pcDEF3-Flag-Smad6C (aa 315-496), pcDEF3-Flag-Smad6N (aa 1-330) were provided by Kohei Miyazono as described previously (Hanyu et al., 2001) . The plasmids were transfected into cells using FuGENE6 reagent (Roche Diagnostics, Indianapolis, IN, USA).
Yeast two-hybrid screening
The two-hybrid analysis was carried out essentially as described previously , using pACTII (for GAL4 activator domain) (Li et al., 1994) and pBTM116 (for LexA DNA-binding domain) (Vojtek et al., 1993) . The cDNA encoding full-length Cas-L was subcloned into pBTM116. The resulting plasmid, pBTM116-Cas-L, was used as bait in a twohybrid screen of a cDNA library of human HTLV-I infected T cell line (SLB-I) in Saccharomyces cerevisiae L40 according to the Matchmaker Two-Hybrid System Protocol (BD Biosciences Clontech, Palo Alto, CA, USA). Positive yeast clones were selected for histidine prototrophy and expression of b-gal. Plasmids containing cDNA clones were rescued from yeast and characterized by DNA sequencing. Concomitantly, those plasmids were introduced back to yeast strain L40 by a polyethylene glycol/lithium acetate method (Bartel et al., 1993) . Colonies were grown on selective synthetic medium and were examined for histidine prototrophy and b-gal activity.
In vitro cell proliferation assay Cell proliferation assay was performed as described previously. In brief, cells were incubated in 96-well plates in media alone or in the presence of TGF-b (0.1, 1.0 or 10 ng/ml each) (R&D Systems, Minneapolis, MN, USA), or vehicle control for a total volume of 100 ml (5Â 10 3 cells/well). After 24 h of incubation at 371C, Tetra Color ONE solution (Seikagaku, Tokyo, Japan) was added to each well. After another 2 h of incubation, fluorescence intensity was measured at 490 nm using a microplate reader (Bio-Rad, Hercules, CA, USA). All samples were tested in triplicate. Values represent the means of triplicate wells, and the s.e. of the mean was under 15%.
Immunocytochemistry
For fluorescent microscopy experiments using 293T cells, cells were treated and stained according to the methods described previously (Ohnuma et al., 2004) . In brief, 293T cells (5 Â 10 4 cells/ml) were grown on coverslips in six-well plates, and transfected with c-myc-tagged Cas-L and Flag-tagged Smad6 or Smad7. The cells were fixed in 4% phosphatebuffered saline-paraformaldehyde solution for 15 min, followed by permeabilization with 0.1% Triton X-100 for 5 min. After blocking with TNB Blocking Buffer (TSA Fluorescence Systems, Perkin-Elmer Life Sciences, Boston, MA, USA), slips were stained with Cy3-labeled anti-c-myc mAb (Sigma, Saint Louis, MO, USA), and fluorescein isothiocynate (FITC)-labeled anti-Flag mAb (SIGMA) over night. After washing, slides were mounted with Prolong Antifade Kit (Molecular Probes, Eugene, OR, USA), and examined by confocal microscope with 40 objective lenses (IX70, Olympus, Tokyo, Japan) using laser excitation at 488 nm.
Immunoprecipitation, SDS-PAGE and immunoblotting
Protein (600 mg) from total cell lysates were diluted in the same final volume of NP-40 buffer (1% NP-40, 0.5% sodium deoxycholate, 5 mM ethylenediaminetetraacetic acid, 50 mM Tris-HCl (pH 8.0), 0.15 M NaCl), containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM NaF, 1 mM Na 3 VO 4 ,
